Mental Health Blogs

Second quarter financial results are out today for Bristol-Myers Squibb and the results for its atypical antipsychotic Abilify are astounding: worldwide sales of the drug reached $643 million in the quarter, an increase of 22 percent over the previous year. US sales were $518 million, a startling 29 percent increase over the second quarter of 2008. All of which is proof that the company’s Abilify as an anti-depesant advertising has paid off handsomely for BMS.

As for patients, well that’s another story.

Go to Source

Related posts:

1. Cymbalta Sales Way Up
2. Bloomberg Dubs Abilify A "Mood Stabilizer"
3. Wyeth Again Fails To Detail Pristiq Sales
4. Lexapro Sales Stabilized By Lexapro Sales To Teens
5. AstraZeneca To Pay Feds $520 Million To Settle Seroquel Claims